Evoq Technologies has announced the official US Food and Drug Administration (FDA) registration of its Twilight dark-adaptation testing instrument as a Class I medical device, now available for sale in the United States.

According to the company, Twilight facilitates the detection of age-related macular degeneration (AMD), diabetic eye disease, and inherited retinal disease. It can be used by technicians in any clinical setting to quickly perform screening for signs of these diseases, without the need for dark rooms, pupil dilation, or disruption to clinic flow.

Testing with the device is reimbursable under CPT 92284 for patients who qualify.

“Twilight fundamentally changes the diagnostic standard of care by revealing visual dysfunction years earlier, when timely intervention can truly make a difference in patient outcomes,” Daniel Lindgren, CEO and founder of Evoq Technologies, stated in a press release.

For more information about Evoq Technologies and Twilight, visit goevoq.com.